Potential use of glucocorticosteroids in CSF1R mutation carriers-current evidence and future directions

Jarosław Dulski, E. Richard Stanley, Violeta Chitu, Zbigniew K. Wszolek

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

We recently found that glucocorticosteroids (GCs) have protective effects in CSF1R mutation carriers against developing symptomatic CSF1R-related leukoencephalopathy. Our findings were subsequently confirmed in a mouse model study. We have received many questions from patients, their families, patient organisations, and healthcare practitioners about the optimal type of GCs, the dose, the route of administration, and application timing. This paper attempts to answer the most urgent of these questions based on our previous studies and personal observations. Despite the promising observations, more research on larger patient groups is needed to elucidate the beneficial actions of GCs in CSF1R mutation carriers.

Original languageEnglish (US)
Pages (from-to)444-449
Number of pages6
JournalNeurologia i Neurochirurgia Polska
Volume57
Issue number5
DOIs
StatePublished - 2023

Keywords

  • glucocorticosteroids
  • hereditary
  • leukoencephalopathy
  • spheroids

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Potential use of glucocorticosteroids in CSF1R mutation carriers-current evidence and future directions'. Together they form a unique fingerprint.

Cite this